A Phase 2 interventional study of dabrafenib and trametinib in Solid Tumours, sponsored by GlaxoSmithKline. Completed at 2 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2017-07-24.
Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment
This is a Japanese Phase I/II, open-label, non-controlled study to evaluate the safety, tolerability, pharmacokinetic profile, and efficacy of the combination of GSK2118436 and GSK1120212 in subjects with BRAF V600E/K mutation positive advanced solid tumors (Phase I part) and BRAF V600E/K mutation positive cutaneous melanoma (Phase II part).
This is a Japanese Phase I/II, open-label, non-controlled study to evaluate the safety, tolerability, pharmacokinetic profile, and efficacy of the combination of GSK2118436 and GSK1120212 in subjects with BRAF V600E/K mutation positive advanced solid tumors (Phase I part) and BRAF V600E/K mutation positive cutaneous melanoma (Phase II part). Phase I part is designed to primarily assess the safety and tolerability of GSK2118436 and GSK1120212 combination therapy in subjects with BRAF V600E/K mutation positive advanced solid tumors. Six evaluable subjects will be enrolled into Phase I part and receive the combination therapy of GSK2118436 (150 mg, twice daily) and GSK1120212 (2 mg, once daily). A decision for starting Phase II part will be made by careful review based on available safety, tolerability and pharmacokinetic data in Phase I part. Phase II part is designed to primarily evaluate ORR of the combination as first-line therapy in subjects with unresectable (Stage IIIC) or metastatic (Stage IV) BRAF V600E/K mutation positive cutaneous melanoma. Subjects who have had prior systemic anti-cancer treatment in the advanced or metastatic setting will not be eligible for Phase II part although prior systemic treatment in the adjuvant setting will be allowed. Six evaluable subjects will be enrolled in Phase II part.
3,005 studies on the registry are indexed under Melanoma; 519 are open to participants now.
This study's enrollment of 12 is below the median of 38 across 2,350 interventional studies indexed under Melanoma.
Browse Melanoma studies →GlaxoSmithKline is the lead sponsor of 3,562 studies on the registry; 117 are open to participants now.
Of its 258 completed or terminated interventional studies of FDA-regulated products, 232 (90%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Combination therapy of dabrafenib and trametinib
Drug: dabrafenib · Drug: trametinib
150 mg twice daily
2 mg once daily
Phase I: Number of Participants With Any Adverse Event (AE) and Any Serious Adverse Event (SAE)
An AE is defined as any untoward medical occurrence (MO) in a part. temporally associated with the use of a medicinal product (MP), whether or not considered related to the MP and can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with its use. SAE is defined as any untoward MO that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, a congenital anomaly/birth defect and protocol-specific SAEs:ALT\>=3xupper limit of normal(ULN) and bilirubin\>=2xULN(\>35% direct) (or ALT\>=3xULN, international normalized ratio\>1.5), any new primary cancers, treatment emergent malignancies except basal cell carcinoma, symptomatic or asymptomatic LVEF decrease, retinal pigment epithelial detachment or retinal vein occlusion, pyrexia with hypotension,or dehydration or renal insufficiency,or severe (\>=G3) rigor/chills.
Time frame: From the start of study treatment until 30 days after study treatment discontinuation (average of 1.38 year)
Phase I: Number of Participants With a Dose-limiting Toxicity (DLT)
A DLT was defined as an event occurred during the first 21 days after the first dose of study drugs and met any of the following criteria, according to National Cancer Institutes (NCI) common terminology criteria for AE (CTCAE) grade (G) version 4.0: G4 hematological toxicity; G3 or G4 non-hematologic toxicity (including rash, nausea, vomiting and diarrhea only if uncontrolled with supportive therapy); rash \>=G3 that required dose reduction despite supportive care; a G2 or greater non-hematological toxicity that in the judgment of the investigator and medical monitor; dose interruption of greater than 14 consecutive days due to unresolved toxicity; any new G2 or greater valvular heart disease and significant alteration in cardiac valve morphology from Baseline.
Time frame: From the start of study treatment until 21 days
Phase I: Number of Participants With the Indicated Worst-case Change From Baseline (BL) in the Indicated Clinical Chemistry Parameters (CCPs)
CCPs were graded according to NCI CTCAE grade version 4.0 as: G1, Mild; G2, Moderate; G3, Severe; G4, Life-threatening or disabling; G5, Death. Data are presented for only those parameters (para) for which an increase to G3 or G4 from BL G occurred. CCPs that were not G according to NCI CTCAE criteria, were categorized as High and Low with respect to the normal range. Data are presented only for those para for which the category decreased to Low or increased to High relative to the BL category. The worst-case during the on-therapy period was determined taking into account both scheduled and unscheduled assessments. CCPs included: albumin, alkaline phosphatase, alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin, calcium, creatinine, glucose, potassium, magnesium, sodium, inorganic phosphorus, chloride, lactate dehydrogenase (LDH), total protein, urea/blood urea nitrogen (BUN) and uric acid.
Time frame: From Baseline until the post-treatment Visit (average of 1.38 year)
Phase I: Number of Participants With the Indicated Worst-case Change From Baseline in the Indicated Hematology Parameters
Hematology parameters were summarized according to NCI CTCAE G, version 4.0 as: G1, Mild; G2, Moderate; G3, Severe; G4, Life-threatening or disabling; G5, Death. Data are presented for only those parameters for which an increase to G3 or G4 from Baseline G occurred. For hematology parameters that were not graded according to NCI CTCAE criteria, were categorized as High and Low with respect to the normal range. Data are presented only for those parameters for which the category decreased to Low or increased to High relative to the Baseline category. The worst-case during the on-therapy period was determined taking into account both scheduled and unscheduled assessments. Hematology parameters included: hemoglobin, lymphocytes, total neutrophils, platelet count, white blood cell (WBC) counts, basophils, eosinophils, hematocrit, mean corpuscular hemoglobin concentration (MCHC), mean corpuscular hemoglobin (MCH), mean corpuscular volume (MCV), monocytes and red blood cell (RBC) count.
Time frame: From Baseline until the post-treatment Visit (average of 1.38 year)
Phase I: Number of Participants With the Indicated Urinalysis Parameters
Urine samples were collected for urine dipstick analysis at Baseline and at the post-treatment Visit. The number of participants with negative (absence) and positive (presence: trace, 1+, 2+, 3+, 4+ or 5+) results for urine occult blood (UOB), urine glucose (UGLU), urine ketones (UKET), urine protein (UP) and urine urobilinogen (UUBIL) were summarized. The Baseline value is defined as the last pre-treatment value observed.
Time frame: From Baseline until the post-treatment Visit (average of 1.38 year)
Phase I: Number of Participants With the Indicated Worst-case On-therapy Change From Baseline in Eastern Cooperative Oncology Group (ECOG) Performance (Pef) Status
The ECOG pef status 5-point scale is used to assess how a participant's disease is progressing, to assess how the disease affects the daily living abilities of the par. and to determine appropriate treatment and prognosis: G0, fully active, able to carry on all pre-disease pef without restriction. G1, restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, example, light house work, office work. G2, ambulatory and capable of all selfcare, but unable to carry out any work activities; up and about \>50 percent (%) of waking hrs. G3, capable of only limited selfcare; confined to bed or chair \>50% of waking hrs. G4, completely disabled; cannot carry on any selfcare; totally confined to bed or chair. G5, dead. The worst-case during the on-therapy period was determined taking into account both scheduled and unscheduled assessments. Number of par. who improved, had no change, or deteriorated in pef status from BL is summarized.
Time frame: From Baseline until the post-treatment Visit (average of 1.38 year)
Phase I: Number of Participants With Worst-case On-therapy Increase From Baseline in Systolic and Diastolic Blood Pressure to Grade 2 or Grade 3
Systolic blood pressure (SBP) and diastolic blood pressure (DBP) values were graded using (NCI CTCAE version 4.0). SBP was categorized as: G1 (Increase to \>=120 to 140 millimeters of mercury \[mmHg\]), G2 (Increase to \>=140 to \<160 mmHg), and G3 (Increase to \>=160 mmHg). DBP was categorized as: G1 (Increase to \>=80 to \<90 mmHg), G2 (Increase to \>=90 to \<100 mmHg), and G3 (Increase to \>=100 mmHg). The worst-case during the on-therapy period was determined taking into account both scheduled and unscheduled assessments. An increase is defined as an increase in the CTCAE grade relative to the Baseline grade. Participants with missing Baseline values were assumed to have a Baseline value of G0.
Time frame: From Baseline until the post-treatment Visit (average of 1.38 year)
Phase I: Number of Participants With Worst-case On-therapy Change From Baseline in Heart Rate
Change from Baseline in heart rate is categorized as decrease to \<60 beats per minute (bpm), change to normal or no change, and increase to \>100 bpm relative to the Baseline value. Participants with a missing Baseline value are assumed to have a normal Baseline value. Participants were counted twice if the participant's heart rate value decreased to \<60 bpm and increased to \>100 bpm post-Baseline. The worst-case during the on-therapy period was determined taking into account both scheduled and unscheduled assessments.
Time frame: From Baseline until the post-treatment Visit (average of 1.38 year)
Phase I: Number of Participants With Worst-case On-therapy Change From Baseline in Temperature
Change from Baseline in temperature is categorized as a decrease to \<=35 degrees celsius (C), change to normal or no change as 35-38 degrees C, and increase to \>=38 degrees C relative to the Baseline value. Participants with a missing Baseline value are assumed to have a normal Baseline value. Participants were counted twice if the participant temperature value decreased to \<=35 degrees C and increased to \>=38 degrees C post-Baseline. The worst-case during the on-therapy period was determined taking into account both scheduled and unscheduled assessments.
Time frame: From Baseline until the post-treatment Visit (average of 1.38 years)
Phase I: Change From Baseline in Oxygen Saturation (SpO2) Measured Via Pulse Oxymetry at the Indicated Time Points
Oxygen saturation measures the capacity of blood to transport oxygen to other parts of the body. Oxygen binds to hemoglobin in red blood cells when moving through the lungs. A pulse oximeter uses two frequencies of light (red and infrared) to determine the percentage of hemoglobin in the blood that is saturated with oxygen,that is called as blood oxygen saturation or SpO2. Change from Baseline was calculated as the individual post-Baseline value (Days 8,15; Weeks 3 to 136 and post-treatment Visit) minus the Baseline value. The Baseline value is defined as the last pre-treatment value observed.
Time frame: From Baseline until the post-treatment Visit (average of 1.38 year)
Phase I: Change From Baseline in Weight at the Indicated Time Points
Mean change in body weight from Baseline was determined. Change from Baseline was calculated as the individual post-Baseline value (Weeks 3 to 136 and post-treatment Visit) minus the Baseline value. The Baseline value is defined as the last pre-treatment value observed.
Time frame: From Baseline until the post-treatment Visit ( average of 1.38 year)
Phase I: Number of Participants With the Indicated Electrocardiogram (ECG) Findings at the Indicated Time Points
Single twelve (12)-lead ECGs were perfomred at Baseline, Weeks 3 to 132 and post-treatment Visit. ECG findings were categorized as: normal, abnormal - clinically significant (CS), or abnormal - not clinically significant (NCS), as determined by the investigator.
Time frame: From Baseline until the post-treatment Visit (average of 1.38 year)
Phase I: Number of Participants With Worst-case On-therapy Change From Baseline in Left Ventricular Ejection Fraction (LVEF) as Assessed by Echocardiogram (ECHO)
Absolute change from Baseline in LVEF were summarized at each scheduled assessment time and in the worst-case post Baseline. Only the post Baseline assessments that used the same method (ECHO or Multi Gated Acquisition Scan \[MUGA\]) as the Baseline assessments were used to derive the change from Baseline. The change from Baseline was categorized as: any increase; no change; 0-\<10 Decrease, 10-19 Decrease, \>=20 Decrease, \>=10 Decrease and \>= lower limit of normal (LLN), \>=10 Decrease and below LLN, \>=20 Decrease and \>=LLN and \>=20 Decrease and below LLN. The worst-case during the on-therapy period was determined taking into account both scheduled and unscheduled assessments.
Time frame: From Baseline until the post-treatment Visit (average of 1.38 years)
Phase II: Number of Participant With Confirmed Overall Response
Confirmed overall response (ORR) is defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. RECIST is a set of rules that define when tumors in cancer participants improve ("respond"), stay the same ("stabilize"), or worsen ("progress") during treatment. CR is defined as disappearance of all target lesions. PR is defined as at least a 30% decrease in the sum of the diameters of target lesions after treatment from Baseline (before study drug administration). ORR was assessed by investigator and blinded independent central review (BICR).
Time frame: Every 8 weeks from start of the treatment until disease progression, death, or withdrawal of consent (average of 1.38 years)
Phase I: Area Under the Plasma Concentration Versus Time Curve (AUC) of GSK2118436 and Metabolites, and GSK1120212 After Single and Repeat Dose
Blood samples were collected from each par. at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hr after administration of GSK2118436 + GSK1120212 on Day 1 (single dose) and at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 12 hr post-dose on Day 21 (repeat dose) for PK analysis. GSK2118436 metabolites included GSK2285403, GSK2298683, and GSK2167542. AUC from time zero to last quantifiable concentration (concn) (AUC\[0-t\]) was determined using the linear trapezoidal rule for increasing concn and the logarithmic trapezoidal rule for decreasing. The AUC from time zero extrapolated to infinity (AUC\[0-inf\] was calculated, where data permit, as the sum of AUC(0-t) and Ct/z, where Ct is the observed plasma concn obtained from the log-linear regression analysis of the last quantifiable time-point and z is the terminal phase rate constant. Area under the concentration-time curve over 12 hr and 24 hr dosing interval is called AUC\[0-12\] and AUC\[0-24\]. AUC(0-inf) was calculated only at Day 1.
Time frame: At pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hr after administration of GSK2118436 + GSK1120212 on Day 1 (single dose) and at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 12 hr on Day 21 (repeat dose)
Phase I: Maximum Plasma Concentration (Cmax) of GSK2118436 and Metabolites, and GSK1120212 After a Single and Repeat Dose
Blood samples were collected from each participant at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hr after administration of GSK2118436 + GSK1120212 on Day 1 (single dose) and at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 12 hr post-dose on Day 21 (repeat dose) for PK analysis. GSK2118436 metabolites included GSK2285403, GSK2298683 and GSK2167542. Cmax was determined from the raw concentration-time data.
Time frame: At pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hr after administration of GSK2118436 + GSK1120212 on Day 1 (single dose) and at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 12 hr on Day 21 (repeat dose)
Phase I: Plasma Trough Concentration (Ctau) of GSK2118436 and Metabolites, and GSK1120212 After a Single and Repeat Dose
Trough concentration is the lowest level that a drug is present in the body. Pre-dose (trough) blood samples were collected on Day 8, Day 15, Weeks 3, 8, 16 and 24 for estimating plasma trough concentration. GSK2118436 metabolites included GSK2285403, GSK2298683, and GSK2167542. Ctau was determined from the raw concentration-time data.
Time frame: At pre-dose on Day 8, Day 15, Weeks 3, 8, 16 and 24
Phase I: Time of Occurrence of Cmax (Tmax) and Terminal Phase Half Life (t1/2) of GSK2118436 and Metabolites, and GSK1120212 After a Single and Repeat Dose
Blood samples were collected from each participant at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hr after administration of GSK2118436 + GSK1120212 on Day 1 (single dose) and at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 12 hr post-dose on Day 21 (repeat dose) for PK analysis. GSK2118436 metabolites included GSK2285403, GSK2298683, and GSK2167542. Tmax is defined as the time of occurrence of Cmax. Tmax was determined directly from the raw concentration-time data. The apparent terminal elimination half-life (t1/2) obtained as the ratio of ln2/lamdaz, where lamdaz is the terminal phase rate constant estimated by linear regression analysis of the log transformed concentration-time data. . T1/2 was calculated only at Day 1.
Time frame: At pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hr after administration of GSK2118436 + GSK1120212 on Day 1 (single dose) and at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 12 hr on Day 21 (repeat dose)
Phase I: Number of Participants With Confirmed Overall Response Rate
Confirmed ORR is defined as the percentage of participants with a confirmed CR or PR according to RECIST, version 1.1. RECIST is a set of rules that define when tumors in cancer participants improve ("respond"), stay the same ("stabilize"), or worsen ("progress") during treatment. CR is defined as the disappearance of all target lesions. PR is defined as at least a 30% decrease in the sum of the diameters of target lesions after treatment from Baseline (before study drug administration). ORR was assessed by investigator and BICR.
Time frame: Every 8 weeks from start of the treatment until disease progression, death, or withdrawal of consent (average of 1.38 years)
Phase I: Number of Participants With Unconfirmed Overall Response Rate
ORR is defined as the percentage of participants with an unconfirmed CR or PR according to RECIST version 1.1. RECIST is a set of rules that define when tumors in cancer participants improve ("respond"), stay the same ("stabilize"), or worsen ("progress") during treatment. CR is defined as disappearance of all target lesions. Partial response is defined as at least a 30% decrease in the sum of the diameters of target lesions after treatment from Baseline (before study drug administration). Unconfirmed ORR was assessed by investigator and BICR.
Time frame: Every 8 weeks from start of the treatment until disease progression, death, or withdrawal of consent (average of 1.38 years)
Phase I: Progression Free Survival (PFS)
PFS is defined as the time from the first dose of study treatment to the earliest date of disease progression or death due to any cause. The length of this interval is estimated as the date of death or disease progression minus the date of first dose plus one day. The date of documented disease progression is defined as the date of disease progression based on radiologic evidence. Participants with documented date of disease progresssion or death and who had not received subsequent anticancer treatment prior to the date of documented disease progression or death were included in the analysis of PFS. PFS was assessed by investigator and BICR. Please note the values of the Full Range (min, max) are described irregardless of censoring at data cut-off.
Time frame: From start of the treatment until disease progression or death (average of 1.38 years)
Phase I: Duration of Response
Duration of response is defined as the time from the first documented evidence of CR or PR until disease progression or death due to any cause among participants with confirmed CR or PR. The participant who showed a CR or PR was included in the analysis of duration of response. Duration of response was assessed by investigator and BICR. Please note the values of the Full Range (min, max) are described irregardless of censoring at data cut-off.
Time frame: From start of the treatment until disease progression or death (average of 1.38 years)
Phase II: Number of Participants With Unconfirmed Overall Response
ORR is defined as the percentage of participants with an unconfirmed CR or PR according to RECIST version 1.1. RECIST is a set of rules that define when tumors in cancer participants improve ("respond"), stay the same ("stabilize"), or worsen ("progress") during treatment. CR is defined as disappearance of all target lesions. Partial response is defined as at least a 30% decrease in the sum of the diameters of target lesions after treatment from Baseline (before study drug administration). Unconfirmed ORR was assessed by investigator and BICR.
Time frame: Every 8 weeks from start of the treatment until disease progression, death, or withdrawal of consent (average of 1.38 years)
Phase II: Progression Free Survival (PFS)
PFS is defined as the time from the first dose of study treatment to the earliest date of disease progression or death due to any cause. The length of this interval is estimated as the date of death or disease progression minus the date of first dose plus one day. The date of documented disease progression is defined as the date of disease progression based on radiologic evidence. Participants with documented date of disease progresssion or death and who had not received subsequent anticancer treatment prior to the date of documented disease progression or death were included in the analysis of PFS. PFS was assessed by investigator and BICR. Please note the values of the Full Range (min, max) are described irregardless of censoring at data cut-off.
Time frame: From start of the treatment until disease progression or death (average of 1.38 years)
Phase II: Duration of Response
Duration of response is defined as the time from the first documented evidence of CR or PR until disease progression or death due to any cause among participants with confirmed CR or PR. The participant who showed a CR or PR was included in the analysis of duration of response. Duration of response was assessed by investigator and BICR. Please note the values of the Full Range (min, max) are described irregardless of censoring at data cut-off.
Time frame: From start of the treatment until disease progression or death (average of 1.38 years)
Phase II: Number of Participants With Any Adverse Event and Any Serious Adverse Event
An AE is defined as any untoward MO in a part. temporally associated with the use of a MP, whether or not considered related to the MP and can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with its use. SAE is defined as any untoward MO that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, a congenital anomaly/birth defect and protocol-specific SAEs:ALT\>=3xULN and bilirubin\>=2xULN(\>35% direct) (or ALT\>=3xULN, international normalized ratio\>1.5), any new primary cancers, treatment emergent malignancies except basal cell carcinoma, symptomatic or asymptomatic LVEF decrease, retinal pigment epithelial detachment or retinal vein occlusion, pyrexia with hypotension,or dehydration or renal insufficiency,or severe (\>=G3) rigor/chills.
Time frame: From the start of study treatment until 30 days after study treatment discontinuation (average of 1.38 years)
Phase II: Number of Participants With the Indicated Worst-case Change From Baseline in the Indicated Clinical Chemistry Parameters
CCPs were graded according to NCI CTCAE garde version 4.0 as: G1, Mild; G2, Moderate; G3, Severe; G4, Life-threatening or disabling; G5, Death. Data are presented for only those parameters for which an increase to G3 or G4 from Baseline grade occurred. CCPs that were not graded according to NCI CTCAE criteria, were categorized as High and Low with respect to the normal range. Data are presented only for those parameters for which the category decreased to Low or increased to High relative to the Baseline category. The worst-case during the on-therapy period was determined taking into account both scheduled and unscheduled assessments. CCPs included: albumin, alkaline phosphatase, ALT, AST, total bilirubin, calcium, creatinine, glucose, potassium, magnesium, sodium, inorganic phosphorus, chloride, LDH, total protein, urea/BUN and uric acid.
Time frame: From Baseline until the post-treatment Visit (average of 1.38 years)
Phase II: Number of Participants With the Indicated Worst-case Change From Baseline in the Indicated Hematology Parameters
Hematology parameters were summarized according to NCI CTCAE G, version 4.0 as: G1, Mild; G2, Moderate; G3, Severe; G4, Life-threatening or disabling; G5, Death. Data are presented for only those parameters for which an increase to G3 or G4 from Baseline G occurred. For hematology parameters that were not graded according to NCI CTCAE criteria, were categorized as High and Low with respect to the normal range. Data are presented only for those parameters for which the category decreased to Low or increased to High relative to the Baseline category. The worst-case during the on-therapy period was determined taking into account both scheduled and unscheduled assessments. Hematology parameters included: hemoglobin, lymphocytes, total neutrophils, platelet count, WBC counts, basophils, eosinophils, hematocrit, MCHC, MCH, MCV, monocytes and RBC count.
Time frame: From Baseline until the post-treatment Visit (average of 1.38 years)
Phase II: Number of Participants With the Indicated Urinalysis Results
Urine samples were collected for urine dipstick analysis at Baseline and at the post-treatment Visit. The number of participants with negative (absence) and positive (presence: trace, 1+, 2+, 3+, 4+ or 5+) results for UOB, UGLU, UKET, UP and UUBIL were summarized. The Baseline value is defined as the last pre-treatment value observed.
Time frame: From Baseline until the post-treatment Visit (average of 1.38 years)
Phase II: Number of Participants With the Indicated Worst-case On-therapy Change From Baseline in ECOG Perormance Status
The ECOG pef status 5-point scale is used to assess how a participant's disease is progressing, to assess how the disease affects the daily living abilities of the par. and to determine appropriate treatment and prognosis: G0, fully active, able to carry on all pre-disease pef without restriction. G1, restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, example, light house work, office work. G2, ambulatory and capable of all selfcare, but unable to carry out any work activities; up and about \>50% of waking hrs. G3, capable of only limited selfcare; confined to bed or chair \>50% of waking hrs. G4, completely disabled; cannot carry on any selfcare; totally confined to bed or chair. G5, dead. The worst-case during the on-therapy period was determined taking into account both scheduled and unscheduled assessments. Number of par. who improved, had no change, or deteriorated in pef status from BL is summarized.
Time frame: From Baseline until the post-treatment Visit (average of 1.38 years)
Phase II: Number of Participants With Worst-case On-therapy Increase From Baseline in Systolic and Diastolic Blood Pressure to Grade 2 or Grade 3
SBP and DBP values were graded using (NCI CTCAE version 4.0). SBP was categorized as: G1 (Increase to \>=120 to 140 mmHg), G2 (Increase to \>=140 to \<160 mmHg), and G3 (Increase to \>=160 mmHg). DBP was categorized as: G1 (Increase to \>=80 to \<90 mmHg), G2 (Increase to \>=90 to \<100 mmHg), and G3 (Increase to \>=100 mmHg). The worst-case during the on-therapy period was determined taking into account both scheduled and unscheduled assessments. An increase is defined as an increase in the CTCAE grade relative to the Baseline grade. Participants with missing Baseline values were assumed to have a Baseline value of G0.
Time frame: From Baseline until the post-treatment Visit (average of 1.38 years)
Phase II: Number of Participants With Worst-case On-therapy Change From Baseline in Heart Rate
Change from Baseline in heart rate is categorized as decrease to \<60 bpm, change to normal or no change, and increase to \>100 bpm relative to the Baseline value. Participants with a missing Baseline value are assumed to have a normal Baseline value. Participants were counted twice if the participant's heart rate value decreased to \<60 bpm and increased to \>100 bpm post-Baseline. The worst-case during the on-therapy period was determined taking into account both scheduled and unscheduled assessments.
Time frame: From Baseline until the post-treatment Visit (average of 1.38 years)
Phase II: Number of Participants With Worst-case On-therapy Change From Baseline in Temperature
Change from Baseline in temperature is categorized as a decrease to \<=35 degrees C, change to normal or no change as 35-38 degrees C, and increase to \>=38 degrees C relative to the Baseline value. Participants with a missing Baseline value are assumed to have a normal Baseline value. Participants were counted twice if the participant temperature value decreased to \<=35 degrees C and increased to \>=38 degrees C post-Baseline. The worst-case during the on-therapy period was determined taking into account both scheduled and unscheduled assessments.
Time frame: From Baseline until the post-treatment Visit (average of 1.38 years)
Phase II: Change From Baseline in Oxygen Saturation Measured Via Pulse Oxymetry at the Indicated Time Points
Oxygen saturation measures the capacity of blood to transport oxygen to other parts of the body. Oxygen binds to hemoglobin in red blood cells when moving through the lungs. A pulse oximeter uses two frequencies of light (red and infrared) to determine the percentage of hemoglobin in the blood that is saturated with oxygen, that is called as blood oxygen saturation, or SpO2. Change from Baseline was calculated as the individual post-Baseline value (Days 8 and 15; Weeks 3 to 132 and post-treatment Visit) minus the Baseline value. The Baseline value is defined as the last pre-treatment value observed.
Time frame: From Baseline until the post-treatment Visit (average of 1.38 years)
Phase II: Change From Baseline in Weight at the Indicated Time Points
Mean change in body weight from baseline was determined. Change from Baseline was calculated as the individual post-Baseline value (Weeks 3 to 132 and post-treatment Visit) minus the Baseline value. The Baseline value is defined as the last pre-treatment value observed.
Time frame: From Baseline until the post-treatment Visit (average of 1.38 years)
Phase II: Number of Participants With the Indicated Electrocardiogram Findings at the Indicated Time Points
Single 12-lead ECGs were performed at Baseline, Weeks 3 to 132 and post-treatment Visit. ECG findings were categorized as: normal, abnormal - CS, or abnormal - NCS, as determined by the investigator.
Time frame: From Baseline until the post-treatment Visit (average of 1.38 years)
Phase II: Number of Participants With Worst-case On-therapy Change From Baseline in Left Ventricular Ejection Fraction as Assessed by Echocardiogram
Absolute change from Baseline in LVEF were summarized at each scheduled assessment time and in the worst-case post Baseline. Only the post Baseline assessments that used the same method (ECHO or MUGA) as the Baseline assessments were used to derive the change from Baseline. The change from Baseline was categorized as: any increase; no change; 0-\<10 Decrease, 10-19 Decrease, \>=20 Decrease, \>=10 Decrease and \>= LLN, \>=10 Decrease and below LLN, \>=20 Decrease and \>=LLN and \>=20 Decrease and below LLN. The worst-case during the on-therapy period was determined taking into account both scheduled and unscheduled assessments.
Time frame: From Baseline until the post-treatment Visit (average of 1.38 years)
| Milestone | Phase I: GSK2118436 150 mg + GSK1120212 2 mg | Phase II: GSK2118436 150 mg + GSK1120212 2 mg |
|---|---|---|
| Started | 6 | 6 |
| Completed | 6 | 5 |
| Not completed | 0 | 1 |
| Withdrew: Adverse event | 0 | 1 |
An AE is defined as any untoward medical occurrence (MO) in a part. temporally associated with the use of a medicinal product (MP), whether or not considered related to the MP and can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with its use. SAE is defined as any untoward MO that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, a congenital anomaly/birth defect and protocol-specific SAEs:ALT\>=3xupper limit of normal(ULN) and bilirubin\>=2xULN(\>35% direct) (or ALT\>=3xULN, international normalized ratio\>1.5), any new primary cancers, treatment emergent malignancies except basal cell carcinoma, symptomatic or asymptomatic LVEF decrease, retinal pigment epithelial detachment or retinal vein occlusion, pyrexia with hypotension,or dehydration or renal insufficiency,or severe (\>=G3) rigor/chills.
| Participants | Phase I: GSK2118436 150 mg + GSK1120212 2 mg |
|---|---|
| Any AEs | 6 |
| Any SAEs | 1 |
A DLT was defined as an event occurred during the first 21 days after the first dose of study drugs and met any of the following criteria, according to National Cancer Institutes (NCI) common terminology criteria for AE (CTCAE) grade (G) version 4.0: G4 hematological toxicity; G3 or G4 non-hematologic toxicity (including rash, nausea, vomiting and diarrhea only if uncontrolled with supportive therapy); rash \>=G3 that required dose reduction despite supportive care; a G2 or greater non-hematological toxicity that in the judgment of the investigator and medical monitor; dose interruption of greater than 14 consecutive days due to unresolved toxicity; any new G2 or greater valvular heart disease and significant alteration in cardiac valve morphology from Baseline.
| Participants | Phase I: GSK2118436 150 mg + GSK1120212 2 mg |
|---|---|
| Phase I: Number of Participants With a Dose-limiting Toxicity (DLT) | 0 |
CCPs were graded according to NCI CTCAE grade version 4.0 as: G1, Mild; G2, Moderate; G3, Severe; G4, Life-threatening or disabling; G5, Death. Data are presented for only those parameters (para) for which an increase to G3 or G4 from BL G occurred. CCPs that were not G according to NCI CTCAE criteria, were categorized as High and Low with respect to the normal range. Data are presented only for those para for which the category decreased to Low or increased to High relative to the BL category. The worst-case during the on-therapy period was determined taking into account both scheduled and unscheduled assessments. CCPs included: albumin, alkaline phosphatase, alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin, calcium, creatinine, glucose, potassium, magnesium, sodium, inorganic phosphorus, chloride, lactate dehydrogenase (LDH), total protein, urea/blood urea nitrogen (BUN) and uric acid.
| Participants | Phase I: GSK2118436 150 mg + GSK1120212 2 mg |
|---|---|
| Alkaline Phosphatase, G3 | 1 |
| ALT, G3 | 1 |
| Inorganic Phosphorous, G4 | 1 |
| Chloride, Low | 2 |
| LDH, Low | 1 |
| LDH, High | 3 |
| Total Protein, Low | 2 |
| Urea/BUN, Low | 1 |
| Urea/BUN, High | 2 |
| Uric acid, Low | 1 |
| Uric acid, High | 1 |
Hematology parameters were summarized according to NCI CTCAE G, version 4.0 as: G1, Mild; G2, Moderate; G3, Severe; G4, Life-threatening or disabling; G5, Death. Data are presented for only those parameters for which an increase to G3 or G4 from Baseline G occurred. For hematology parameters that were not graded according to NCI CTCAE criteria, were categorized as High and Low with respect to the normal range. Data are presented only for those parameters for which the category decreased to Low or increased to High relative to the Baseline category. The worst-case during the on-therapy period was determined taking into account both scheduled and unscheduled assessments. Hematology parameters included: hemoglobin, lymphocytes, total neutrophils, platelet count, white blood cell (WBC) counts, basophils, eosinophils, hematocrit, mean corpuscular hemoglobin concentration (MCHC), mean corpuscular hemoglobin (MCH), mean corpuscular volume (MCV), monocytes and red blood cell (RBC) count.
| Participants | Phase I: GSK2118436 150 mg + GSK1120212 2 mg |
|---|---|
| Lymphocytes, G3 | 1 |
| Total Neutrophils, G3 | 1 |
| Basophils, High | 1 |
| Eosinophils, High | 1 |
| Hematocrit, Low | 3 |
| MCHC, Low | 1 |
| MCH, Low | 2 |
| MCV, Low | 1 |
| Monocytes, Low | 2 |
| Monocytes, High | 3 |
| RBC count, Low | 4 |
Urine samples were collected for urine dipstick analysis at Baseline and at the post-treatment Visit. The number of participants with negative (absence) and positive (presence: trace, 1+, 2+, 3+, 4+ or 5+) results for urine occult blood (UOB), urine glucose (UGLU), urine ketones (UKET), urine protein (UP) and urine urobilinogen (UUBIL) were summarized. The Baseline value is defined as the last pre-treatment value observed.
| Participants | Phase I: GSK2118436 150 mg + GSK1120212 2 mg |
|---|---|
| UOB, Baseline, Negative | 6 |
| UOB, Baseline, Positive | 0 |
| UOB, Post-Treatment, Negative | 2 |
| UOB, Post-Treatment, Positive | 1 |
| UGLU, Baseline, Negative | 6 |
| UGLU, Baseline, Positive | 0 |
| UGLU, Post-Treatment, Negative | 3 |
| UGLU, Post-Treatment, Positive | 0 |
| UKET, Baseline, Negative | 6 |
| UKET, Baseline, Positive | 0 |
| UKET, Post-Treatment, Negative | 3 |
| UKET, Post-Treatment, Positive | 0 |
| UP, Baseline, Negative | 5 |
| UP, Baseline, Positive | 1 |
| UP, Post-Treatment, Negative | 2 |
| UP, Post-Treatment, Positive | 0 |
| UUBIL, Baseline, Negative | 0 |
| UUBIL, Baseline, Positive | 6 |
| UUBIL, Post-Treatment, Negative | 0 |
| UUBIL, Post-Treatment, Positive | 3 |
The ECOG pef status 5-point scale is used to assess how a participant's disease is progressing, to assess how the disease affects the daily living abilities of the par. and to determine appropriate treatment and prognosis: G0, fully active, able to carry on all pre-disease pef without restriction. G1, restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, example, light house work, office work. G2, ambulatory and capable of all selfcare, but unable to carry out any work activities; up and about \>50 percent (%) of waking hrs. G3, capable of only limited selfcare; confined to bed or chair \>50% of waking hrs. G4, completely disabled; cannot carry on any selfcare; totally confined to bed or chair. G5, dead. The worst-case during the on-therapy period was determined taking into account both scheduled and unscheduled assessments. Number of par. who improved, had no change, or deteriorated in pef status from BL is summarized.
| Participants | Phase I: GSK2118436 150 mg + GSK1120212 2 mg |
|---|---|
| Improved | 1 |
| No change | 4 |
| Deteriorated | 1 |
Systolic blood pressure (SBP) and diastolic blood pressure (DBP) values were graded using (NCI CTCAE version 4.0). SBP was categorized as: G1 (Increase to \>=120 to 140 millimeters of mercury \[mmHg\]), G2 (Increase to \>=140 to \<160 mmHg), and G3 (Increase to \>=160 mmHg). DBP was categorized as: G1 (Increase to \>=80 to \<90 mmHg), G2 (Increase to \>=90 to \<100 mmHg), and G3 (Increase to \>=100 mmHg). The worst-case during the on-therapy period was determined taking into account both scheduled and unscheduled assessments. An increase is defined as an increase in the CTCAE grade relative to the Baseline grade. Participants with missing Baseline values were assumed to have a Baseline value of G0.
| Participants | Phase I: GSK2118436 150 mg + GSK1120212 2 mg |
|---|---|
| SBP, Increase to Grade 2 | 3 |
| SBP, Increase to Grade 3 | 0 |
| DBP, Increase to Grade 2 | 2 |
| DBP, Increase to Grade 3 | 1 |
Change from Baseline in heart rate is categorized as decrease to \<60 beats per minute (bpm), change to normal or no change, and increase to \>100 bpm relative to the Baseline value. Participants with a missing Baseline value are assumed to have a normal Baseline value. Participants were counted twice if the participant's heart rate value decreased to \<60 bpm and increased to \>100 bpm post-Baseline. The worst-case during the on-therapy period was determined taking into account both scheduled and unscheduled assessments.
| Participants | Phase I: GSK2118436 150 mg + GSK1120212 2 mg |
|---|---|
| Decrease to <60 bpm | 1 |
| Change to normal or no change | 3 |
| Increase to >100 bpm | 3 |
Change from Baseline in temperature is categorized as a decrease to \<=35 degrees celsius (C), change to normal or no change as 35-38 degrees C, and increase to \>=38 degrees C relative to the Baseline value. Participants with a missing Baseline value are assumed to have a normal Baseline value. Participants were counted twice if the participant temperature value decreased to \<=35 degrees C and increased to \>=38 degrees C post-Baseline. The worst-case during the on-therapy period was determined taking into account both scheduled and unscheduled assessments.
| Participants | Phase I: GSK2118436 150 mg + GSK1120212 2 mg |
|---|---|
| Decrease to <=35 degrees C | 2 |
| Change to normal or no change | 2 |
| Increase to >=38 degrees C | 3 |
Oxygen saturation measures the capacity of blood to transport oxygen to other parts of the body. Oxygen binds to hemoglobin in red blood cells when moving through the lungs. A pulse oximeter uses two frequencies of light (red and infrared) to determine the percentage of hemoglobin in the blood that is saturated with oxygen,that is called as blood oxygen saturation or SpO2. Change from Baseline was calculated as the individual post-Baseline value (Days 8,15; Weeks 3 to 136 and post-treatment Visit) minus the Baseline value. The Baseline value is defined as the last pre-treatment value observed.
| Percentage of oxygen in blood | Phase I: GSK2118436 150 mg + GSK1120212 2 mg |
|---|---|
| Day 8, n=6 | 1.0 ± 0.89 |
| Day 15, n=6 | 0.8 ± 0.75 |
| Week 3, n=6 | 0.2 ± 0.75 |
| Week 8, n=6 | 0.7 ± 1.21 |
| Week 12, n=5 | 1.4 ± 1.67 |
| Week 16, n=6 | 1.2 ± 2.14 |
| Week 20, n=5 | 0.4 ± 1.14 |
| Week 24, n=5 | 0.8 ± 1.92 |
| Week 28, n=5 | 0.8 ± 1.92 |
| Week 32, n=5 | 0.6 ± 1.14 |
| Week 36, n=5 | 0.8 ± 1.30 |
| Week 40, n=4 | 0.5 ± 1.00 |
| Week 44, n=4 | 0.5 ± 2.38 |
| Week 48, n=4 | 0.5 ± 2.08 |
| Week 52, n=2 | -0.5 ± 2.12 |
| Week 56, n=2 | 0.0 ± 0.00 |
| Week 60, n=2 | -0.5 ± 0.71 |
| Week 64, n=2 | 0.0 ± 0.00 |
| Week 68, n=1 | 0.0 ± NA |
| Week 72, n=1 | 1.0 ± NA |
| Week 76, n=1 | 0.0 ± NA |
| Week 80, n=1 | 1.0 ± NA |
| Week 84, n=1 | 0.0 ± NA |
| Week 88, n=1 | 0.0 ± NA |
| Week 92, n=1 | -2.0 ± NA |
| Week 96, n=1 | 0.0 ± NA |
| Week 100, n=1 | 0.0 ± NA |
| Week 104, n=1 | 0.0 ± NA |
| Week 108, n=1 | -1.0 ± NA |
| Week 112, n=1 | 0.0 ± NA |
| Week 116, n=1 | 0.0 ± NA |
| Week 120, n=1 | 0.0 ± NA |
| Week 124, n=1 | 0.0 ± NA |
| Week 128, n=1 | 0.0 ± NA |
| Week 132, n=1 | 0.0 ± NA |
| Week 136, n=1 | 0.0 ± NA |
| Post-Treatment, n=4 | 0.8 ± 0.96 |
Mean change in body weight from Baseline was determined. Change from Baseline was calculated as the individual post-Baseline value (Weeks 3 to 136 and post-treatment Visit) minus the Baseline value. The Baseline value is defined as the last pre-treatment value observed.
| Kilogram (Kg) | Phase I: GSK2118436 150 mg + GSK1120212 2 mg |
|---|---|
| Week 3, n=6 | -4.87 ± 6.046 |
| Week 8, n=6 | -4.43 ± 6.274 |
| Week 12, n=6 | -4.13 ± 6.436 |
| Week 16, n=6 | -4.00 ± 6.801 |
| Week 20, n=5 | -0.62 ± 2.295 |
| Week 24, n=5 | -0.70 ± 1.402 |
| Week 28, n=5 | -0.36 ± 1.850 |
| Week 32, n=5 | -0.38 ± 1.809 |
| Week 36, n=5 | -0.78 ± 1.821 |
| Week 40, n=4 | -1.43 ± 1.305 |
| Week 44, n=4 | -0.68 ± 1.759 |
| Week 48, n=4 | -1.03 ± 2.081 |
| Week 52, n=2 | 0.15 ± 2.475 |
| Week 56, n=2 | -0.30 ± 1.556 |
| Week 60, n=2 | -0.35 ± 2.475 |
| Week 64, n=2 | -0.05 ± 2.475 |
| Week 68, n=1 | -2.60 ± NA |
| Week 72, n=1 | -2.10 ± NA |
| Week 76, n=1 | -1.20 ± NA |
| Week 80, n=1 | -0.70 ± NA |
| Week 84, n=1 | -0.70 ± NA |
| Week 88, n=1 | -1.20 ± NA |
| Week 92, n=1 | -0.80 ± NA |
| Week 96, n=1 | -0.80 ± NA |
| Week 100, n=1 | -0.80 ± NA |
| Week 104, n=1 | -0.50 ± NA |
| Week 108, n=1 | -1.00 ± NA |
| Week 112, n=1 | -1.00 ± NA |
| Week 116, n=1 | -0.50 ± NA |
| Week 120, n=1 | -0.60 ± NA |
| Week 124, n=1 | -0.70 ± NA |
| Week 128, n=1 | -0.60 ± NA |
| Week 132, n=1 | -0.80 ± NA |
| Week 136, n=1 | -0.50 ± NA |
| Post-Treatment, n=4 | -0.05 ± 1.457 |
Single twelve (12)-lead ECGs were perfomred at Baseline, Weeks 3 to 132 and post-treatment Visit. ECG findings were categorized as: normal, abnormal - clinically significant (CS), or abnormal - not clinically significant (NCS), as determined by the investigator.
| Participants | Phase I: GSK2118436 150 mg + GSK1120212 2 mg |
|---|---|
| Baseline, Normal, n=6 | 4 |
| Baseline, Abnormal-NCS, n=6 | 2 |
| Baseline, Abnormal-CS, n=6 | 0 |
| Week 3, Normal, n=6 | 5 |
| Week 3, Abnormal-NCS, n=6 | 1 |
| Week 3, Abnormal-CS, n=6 | 0 |
| Week 12, Normal, n=6 | 5 |
| Week 12, Abnormal-NCS, n=6 | 1 |
| Week 12, Abnormal-CS, n=6 | 0 |
| Week 24, Normal, n=5 | 4 |
| Week 24, Abnormal-NCS, n=5 | 1 |
| Week 24, Abnormal-CS, n=5 | 0 |
| Week 36, Normal, n=5 | 4 |
| Week 36, Abnormal-NCS, n=5 | 1 |
| Week 36, Abnormal-CS, n=5 | 0 |
| Week 48, Normal, n=4 | 2 |
| Week 48, Abnormal-NCS, n=4 | 2 |
| Week 48, Abnormal-CS, n=4 | 0 |
| Week 60, Normal, n=2 | 2 |
| Week 60, Abnormal-NCS, n=2 | 0 |
| Week 60, Abnormal-CS, n=2 | 0 |
| Week 72, Normal, n=1 | 1 |
| Week 72, Abnormal-NCS, n=1 | 0 |
| Week 72, Abnormal-CS, n=1 | 0 |
| Week 84, Normal, n=1 | 1 |
| Week 84, Abnormal-NCS, n=1 | 0 |
| Week 84, Abnormal-CS, n=1 | 0 |
| Week 96, Normal, n=1 | 1 |
| Week 96, Abnormal-NCS, n=1 | 0 |
| Week 96, Abnormal-CS, n=1 | 0 |
| Week 108, Normal, n=1 | 1 |
| Week 108, Abnormal-NCS, n=1 | 0 |
| Week 108, Abnormal-CS, n=1 | 0 |
| Week 120, Normal, n=1 | 1 |
| Week 120, Abnormal-NCS, n=1 | 0 |
| Week 120, Abnormal-CS, n=1 | 0 |
| Week 132, Normal, n=1 | 1 |
| Week 132, Abnormal-NCS, n=1 | 0 |
| Week 132, Abnormal-CS, n=1 | 0 |
| Post-Treatment, Normal, n=3 | 3 |
| Post-Treatment, Abnormal-NCS, n=3 | 0 |
| Post-Treatment, Abnormal-CS, n=3 | 0 |
Absolute change from Baseline in LVEF were summarized at each scheduled assessment time and in the worst-case post Baseline. Only the post Baseline assessments that used the same method (ECHO or Multi Gated Acquisition Scan \[MUGA\]) as the Baseline assessments were used to derive the change from Baseline. The change from Baseline was categorized as: any increase; no change; 0-\<10 Decrease, 10-19 Decrease, \>=20 Decrease, \>=10 Decrease and \>= lower limit of normal (LLN), \>=10 Decrease and below LLN, \>=20 Decrease and \>=LLN and \>=20 Decrease and below LLN. The worst-case during the on-therapy period was determined taking into account both scheduled and unscheduled assessments.
| Participants | Phase I: GSK2118436 150 mg + GSK1120212 2 mg |
|---|---|
| Any Increase | 0 |
| No change | 0 |
| 0-<10 Decrease | 5 |
| 10-19 Decrease | 1 |
| >=20 Decrease | 0 |
| >=10 Decrease and >=LLN | 1 |
| >=10 Decrease and below LLN | 0 |
| >=20 Decrease and >=LLN | 0 |
| >=20 Decrease and below LLN | 0 |
Confirmed overall response (ORR) is defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. RECIST is a set of rules that define when tumors in cancer participants improve ("respond"), stay the same ("stabilize"), or worsen ("progress") during treatment. CR is defined as disappearance of all target lesions. PR is defined as at least a 30% decrease in the sum of the diameters of target lesions after treatment from Baseline (before study drug administration). ORR was assessed by investigator and blinded independent central review (BICR).
| Participants | Phase II: GSK2118436 150 mg + GSK1120212 2 mg |
|---|---|
| Investigator-Assessed | 5 |
| BICR-Assessed | 5 |
Blood samples were collected from each par. at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hr after administration of GSK2118436 + GSK1120212 on Day 1 (single dose) and at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 12 hr post-dose on Day 21 (repeat dose) for PK analysis. GSK2118436 metabolites included GSK2285403, GSK2298683, and GSK2167542. AUC from time zero to last quantifiable concentration (concn) (AUC\[0-t\]) was determined using the linear trapezoidal rule for increasing concn and the logarithmic trapezoidal rule for decreasing. The AUC from time zero extrapolated to infinity (AUC\[0-inf\] was calculated, where data permit, as the sum of AUC(0-t) and Ct/z, where Ct is the observed plasma concn obtained from the log-linear regression analysis of the last quantifiable time-point and z is the terminal phase rate constant. Area under the concentration-time curve over 12 hr and 24 hr dosing interval is called AUC\[0-12\] and AUC\[0-24\]. AUC(0-inf) was calculated only at Day 1.
| hr*nanogram (ng)/mL | Phase I: GSK2118436 150 mg + GSK1120212 2 mg |
|---|---|
| GSK2118436, AUC[0-t], Day 1, n=6 | 12850.5346 ± 37.3 |
| GSK2118436, AUC[0-t], Day 21, n=6 | 10075.3530 ± 32.4 |
| GSK2118436, AUC[0-12], Day 1, n=6 | 11414.9211 ± 41.3 |
| GSK2118436, AUC[0-12], Day 21, n=6 | 10138.0887 ± 33.1 |
| GSK2118436, AUC[0-inf], Day 1, n=6 | 13485.6357 ± 36.9 |
| GSK2285403, AUC[0-t], Day 1, n=6 | 10530.0297 ± 39.4 |
| GSK2285403, AUC[0-t], Day 21, n=6 | 7199.9862 ± 29.9 |
| GSK2285403, AUC[0-12], Day 1, n=6 | 7929.4506 ± 64.3 |
| GSK2285403, AUC[0-12], Day 21, n=6 | 7273.0445 ± 30.6 |
| GSK2285403, AUC[0-inf], Day 1, n=6 | 13903.4979 ± 67.9 |
| GSK2298683, AUC[0-t], day 1, n=6 | 50834.2106 ± 106.0 |
| GSK2298683, AUC[0-t], Day 21, n=6 | 108578.495 ± 36.1 |
| GSK2298683, AUC[0-12], Day 1, n=6 | 18963.4767 ± 255.7 |
| GSK2298683, AUC[0-12], Day 21, n=6 | 113205.044 ± 36.8 |
| GSK2298683, AUC[0-inf], Day 1, n=5 | 125748.810 ± 41.8 |
| GSK2167542, AUC[0-t], Day 1, n=6 | 571.5619 ± 170.4 |
| GSK2167542, AUC[0-t], Day 21, n=6 | 2503.0667 ± 92.7 |
| GSK2167542, AUC[0-12], Day 1, n=6 | 116.1860 ± 269.6 |
| GSK2167542, AUC[0-12], Day 21, n=4 | 2755.2522 ± 122.0 |
| GSK2167542, AUC[0-inf], Day 1, n=1 | 4628.4351 ± NA |
| GSK1120212, AUC[0-t], Day 1, n=6 | 69.3090 ± 50.2 |
| GSK1120212, AUC[0-t], Day 21, n=6 | 261.2787 ± 20.9 |
| GSK1120212, AUC[0-24], Day 1, n=5 | 82.5215 ± 23.1 |
| GSK1120212, AUC[0-24], Day 21, n=6 | 447.9452 ± 25.5 |
| GSK1120212, AUC[0-inf], Day 1, n=5 | 375.5275 ± 23.1 |
Blood samples were collected from each participant at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hr after administration of GSK2118436 + GSK1120212 on Day 1 (single dose) and at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 12 hr post-dose on Day 21 (repeat dose) for PK analysis. GSK2118436 metabolites included GSK2285403, GSK2298683 and GSK2167542. Cmax was determined from the raw concentration-time data.
| ng/mL | Phase I: GSK2118436 150 mg + GSK1120212 2 mg |
|---|---|
| GSK2118436, Day 1 | 2497.383 ± 69.7 |
| GSK2118436, Day 21 | 3431.280 ± 12.0 |
| GSK2285403, Day 1 | 1336.296 ± 70.1 |
| GSK2285403, Day 21 | 1995.847 ± 14.8 |
| GSK2298683, Day 1 | 3689.039 ± 75.5 |
| GSK2298683, Day 21 | 12303.403 ± 32.5 |
| GSK2167542, Day 1 | 50.405 ± 149.7 |
| GSK2167542, Day 21 | 323.863 ± 82.4 |
| GSK1120212, Day 1 | 7.824 ± 112.1 |
| GSK1120212, Day 21 | 32.522 ± 20.2 |
Trough concentration is the lowest level that a drug is present in the body. Pre-dose (trough) blood samples were collected on Day 8, Day 15, Weeks 3, 8, 16 and 24 for estimating plasma trough concentration. GSK2118436 metabolites included GSK2285403, GSK2298683, and GSK2167542. Ctau was determined from the raw concentration-time data.
| ng/mL | Phase I: GSK2118436 150 mg + GSK1120212 2 mg |
|---|---|
| GSK2118436, Day 8, n=6 | 118.36 ± 188.3 |
| GSK2118436, Day 15, n=6 | 84.25 ± 136.2 |
| GSK2118436, Week 3, n=6 | 78.14 ± 149.3 |
| GSK2118436, Week 8, n=6 | 78.29 ± 591.4 |
| GSK2118436, Week 16, n=6 | 105.05 ± 206.4 |
| GSK2118436, Week 24, n=5 | 121.85 ± 183.9 |
| GSK2285403, Day 8, n=6 | 149.61 ± 111.9 |
| GSK2285403, Day 15, n=6 | 106.09 ± 72.8 |
| GSK2285403, Week 3, n=6 | 93.87 ± 82.0 |
| GSK2285403, Week 8, n=6 | 89.12 ± 239.4 |
| GSK2285403, Week 16, n=6 | 100.10 ± 121.8 |
| GSK2285403, Week 24, n=5 | 117.93 ± 121.4 |
| GSK2298683, Day 8, n=6 | 6011.00 ± 39.8 |
| GSK2298683, Day 15, n=6 | 5141.38 ± 39.5 |
| GSK2298683, Week 3, n=6 | 6210.90 ± 51.8 |
| GSK2298683, Week 8, n=6 | 4408.24 ± 65.0 |
| GSK2298683, Week 16, n=6 | 4022.93 ± 39.4 |
| GSK2298683, Week 24, n=5 | 4294.86 ± 51.9 |
| GSK2167542, Day 8, n=6 | 217.73 ± 46.7 |
| GSK2167542, Day 15, n=6 | 161.11 ± 107.5 |
| GSK2167542, Week 3, n=6 | 224.32 ± 83.6 |
| GSK2167542, Week 8, n=6 | 220.93 ± 52.2 |
| GSK2167542, Week 16, n=6 | 270.15 ± 107.5 |
| GSK2167542, Week 24, n=5 | 227.75 ± 101.5 |
| GSK1120212, Day 8, n=6 | 11.36 ± 43.0 |
| GSK1120212, Day 15, n=6 | 12.47 ± 22.4 |
| GSK1120212, Week 3, n=6 | 13.80 ± 25.6 |
| GSK1120212, Week 8, n=6 | 14.52 ± 65.0 |
| GSK1120212, Week 16, n=6 | 13.47 ± 39.4 |
| GSK1120212, Week 24, n=5 | 13.72 ± 41.3 |
Blood samples were collected from each participant at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hr after administration of GSK2118436 + GSK1120212 on Day 1 (single dose) and at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 12 hr post-dose on Day 21 (repeat dose) for PK analysis. GSK2118436 metabolites included GSK2285403, GSK2298683, and GSK2167542. Tmax is defined as the time of occurrence of Cmax. Tmax was determined directly from the raw concentration-time data. The apparent terminal elimination half-life (t1/2) obtained as the ratio of ln2/lamdaz, where lamdaz is the terminal phase rate constant estimated by linear regression analysis of the log transformed concentration-time data. . T1/2 was calculated only at Day 1.
| hr | Phase I: GSK2118436 150 mg + GSK1120212 2 mg |
|---|---|
| GSK2118436, t1/2, Day 1, n=6 | 4.5398 (2.776 to 9.645) |
| GSK2118436, tmax, Day 1, n=6 | 2.425 (1.43 to 3.85) |
| GSK2118436, tmax, Day 21, n=6 | 1.685 (0.97 to 1.97) |
| GSK2285403, t1/2, Day 1, n=6 | 4.2086 (3.574 to 55.294) |
| GSK2285403, tmax, Day 1, n=6 | 3.410 (2.93 to 11.93) |
| GSK2285403, tmax, Day 21, n=6 | 1.950 (1.47 to 2.93) |
| GSK2298683, t1/2, Day 1, n=5 | 15.5414 (11.652 to 21.159) |
| GSK2298683, tmax, Day 1, n=6 | 9.840 (7.92 to 23.82) |
| GSK2298683, tmax, Day 21, n=6 | 4.955 (2.75 to 5.98) |
| GSK2167542, t1/2, Day 1, n=1 | 55.8643 (55.8643 to 55.8643) |
| GSK2167542, tmax, Day 1, n=6 | 23.885 (11.65 to 24.28) |
| GSK2167542, tmax, Day 21, n=6 | 4.505 (1.97 to 9.92) |
| GSK1120212, t1/2, Day 1, n=5 | 89.5954 (39.029 to 126.331) |
| GSK1120212, tmax, Day 1, n=6 | 0.965 (0.92 to 23.82) |
| GSK1120212, tmax, Day 21, n=6 | 1.210 (0.92 to 5.93) |
Confirmed ORR is defined as the percentage of participants with a confirmed CR or PR according to RECIST, version 1.1. RECIST is a set of rules that define when tumors in cancer participants improve ("respond"), stay the same ("stabilize"), or worsen ("progress") during treatment. CR is defined as the disappearance of all target lesions. PR is defined as at least a 30% decrease in the sum of the diameters of target lesions after treatment from Baseline (before study drug administration). ORR was assessed by investigator and BICR.
| Participants | Phase I: GSK2118436 150 mg + GSK1120212 2 mg |
|---|---|
| Investigator-Assessed | 5 |
| BICR-Assessed | 3 |
ORR is defined as the percentage of participants with an unconfirmed CR or PR according to RECIST version 1.1. RECIST is a set of rules that define when tumors in cancer participants improve ("respond"), stay the same ("stabilize"), or worsen ("progress") during treatment. CR is defined as disappearance of all target lesions. Partial response is defined as at least a 30% decrease in the sum of the diameters of target lesions after treatment from Baseline (before study drug administration). Unconfirmed ORR was assessed by investigator and BICR.
| Participants | Phase I: GSK2118436 150 mg + GSK1120212 2 mg |
|---|---|
| Investigator-Assessed | 5 |
| BICR-Assessed | 3 |
PFS is defined as the time from the first dose of study treatment to the earliest date of disease progression or death due to any cause. The length of this interval is estimated as the date of death or disease progression minus the date of first dose plus one day. The date of documented disease progression is defined as the date of disease progression based on radiologic evidence. Participants with documented date of disease progresssion or death and who had not received subsequent anticancer treatment prior to the date of documented disease progression or death were included in the analysis of PFS. PFS was assessed by investigator and BICR. Please note the values of the Full Range (min, max) are described irregardless of censoring at data cut-off.
| Weeks | Phase I: GSK2118436 150 mg + GSK1120212 2 mg |
|---|---|
| Investigator-Assessed, n=6 | NA (16 to 65.1) |
| BICR-Assessed, n=6 | NA (9 to 65.1) |
Duration of response is defined as the time from the first documented evidence of CR or PR until disease progression or death due to any cause among participants with confirmed CR or PR. The participant who showed a CR or PR was included in the analysis of duration of response. Duration of response was assessed by investigator and BICR. Please note the values of the Full Range (min, max) are described irregardless of censoring at data cut-off.
| Weeks | Phase I: GSK2118436 150 mg + GSK1120212 2 mg |
|---|---|
| Investigator-Assessed, n=5 | NA (17.4 to 57.1) |
| BICR-Assessed, n=3 | NA (32.1 to 57.1) |
ORR is defined as the percentage of participants with an unconfirmed CR or PR according to RECIST version 1.1. RECIST is a set of rules that define when tumors in cancer participants improve ("respond"), stay the same ("stabilize"), or worsen ("progress") during treatment. CR is defined as disappearance of all target lesions. Partial response is defined as at least a 30% decrease in the sum of the diameters of target lesions after treatment from Baseline (before study drug administration). Unconfirmed ORR was assessed by investigator and BICR.
| Participants | Phase II: GSK2118436 150 mg + GSK1120212 2 mg |
|---|---|
| Investigator-Assessed | 5 |
| BICR-Assessed | 5 |
PFS is defined as the time from the first dose of study treatment to the earliest date of disease progression or death due to any cause. The length of this interval is estimated as the date of death or disease progression minus the date of first dose plus one day. The date of documented disease progression is defined as the date of disease progression based on radiologic evidence. Participants with documented date of disease progresssion or death and who had not received subsequent anticancer treatment prior to the date of documented disease progression or death were included in the analysis of PFS. PFS was assessed by investigator and BICR. Please note the values of the Full Range (min, max) are described irregardless of censoring at data cut-off.
| Weeks | Phase II: GSK2118436 150 mg + GSK1120212 2 mg |
|---|---|
| Investigator-Assessed, n=6 | NA (19.0 to 128.4) |
| BICR-Assessed, n=6 | NA (19.0 to 128.4) |
Duration of response is defined as the time from the first documented evidence of CR or PR until disease progression or death due to any cause among participants with confirmed CR or PR. The participant who showed a CR or PR was included in the analysis of duration of response. Duration of response was assessed by investigator and BICR. Please note the values of the Full Range (min, max) are described irregardless of censoring at data cut-off.
| Weeks | Phase II: GSK2118436 150 mg + GSK1120212 2 mg |
|---|---|
| Investigator-Assessed, n=5 | NA (16 to 120.1) |
| BICR-Assessed, n=5 | NA (11.1 to 120.1) |
An AE is defined as any untoward MO in a part. temporally associated with the use of a MP, whether or not considered related to the MP and can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with its use. SAE is defined as any untoward MO that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, a congenital anomaly/birth defect and protocol-specific SAEs:ALT\>=3xULN and bilirubin\>=2xULN(\>35% direct) (or ALT\>=3xULN, international normalized ratio\>1.5), any new primary cancers, treatment emergent malignancies except basal cell carcinoma, symptomatic or asymptomatic LVEF decrease, retinal pigment epithelial detachment or retinal vein occlusion, pyrexia with hypotension,or dehydration or renal insufficiency,or severe (\>=G3) rigor/chills.
| Participants | Phase II: GSK2118436 150 mg + GSK1120212 2 mg |
|---|---|
| Any AE | 6 |
| Any SAE | 0 |
CCPs were graded according to NCI CTCAE garde version 4.0 as: G1, Mild; G2, Moderate; G3, Severe; G4, Life-threatening or disabling; G5, Death. Data are presented for only those parameters for which an increase to G3 or G4 from Baseline grade occurred. CCPs that were not graded according to NCI CTCAE criteria, were categorized as High and Low with respect to the normal range. Data are presented only for those parameters for which the category decreased to Low or increased to High relative to the Baseline category. The worst-case during the on-therapy period was determined taking into account both scheduled and unscheduled assessments. CCPs included: albumin, alkaline phosphatase, ALT, AST, total bilirubin, calcium, creatinine, glucose, potassium, magnesium, sodium, inorganic phosphorus, chloride, LDH, total protein, urea/BUN and uric acid.
| Participants | Phase II: GSK2118436 150 mg + GSK1120212 2 mg |
|---|---|
| Inorganic Phosphorous, G3 | 2 |
| Chloride, High | 2 |
| LDH, High | 5 |
| Total Protein, Low | 2 |
| Urea/BUN, High | 1 |
| Uric acid, Low | 1 |
Hematology parameters were summarized according to NCI CTCAE G, version 4.0 as: G1, Mild; G2, Moderate; G3, Severe; G4, Life-threatening or disabling; G5, Death. Data are presented for only those parameters for which an increase to G3 or G4 from Baseline G occurred. For hematology parameters that were not graded according to NCI CTCAE criteria, were categorized as High and Low with respect to the normal range. Data are presented only for those parameters for which the category decreased to Low or increased to High relative to the Baseline category. The worst-case during the on-therapy period was determined taking into account both scheduled and unscheduled assessments. Hematology parameters included: hemoglobin, lymphocytes, total neutrophils, platelet count, WBC counts, basophils, eosinophils, hematocrit, MCHC, MCH, MCV, monocytes and RBC count.
| Participants | Phase II: GSK2118436 150 mg + GSK1120212 2 mg |
|---|---|
| Total Neutrophils, G3 | 1 |
| Eosinophils, High | 1 |
| Hematocrit, Low | 2 |
| MCHC, Low | 1 |
| MCH, Low | 1 |
| MCV, Low | 1 |
| MCV, High | 1 |
| Monocytes, Low | 3 |
| Monocytes, High | 4 |
| RBC count, Low | 1 |
| RBC count, High | 1 |
Urine samples were collected for urine dipstick analysis at Baseline and at the post-treatment Visit. The number of participants with negative (absence) and positive (presence: trace, 1+, 2+, 3+, 4+ or 5+) results for UOB, UGLU, UKET, UP and UUBIL were summarized. The Baseline value is defined as the last pre-treatment value observed.
| Participants | Phase II: GSK2118436 150 mg + GSK1120212 2 mg |
|---|---|
| UOB, Baseline, Negative | 6 |
| UOB, Baseline, Positive | 0 |
| UOB, Post-Treatment, Negative | 3 |
| UOB, Post-Treatment, Positive | 0 |
| UGLU, Baseline, Negative | 6 |
| UGLU, Baseline, Positive | 0 |
| UGLU, Post-Treatment, Negative | 2 |
| UGLU, Post-Treatment, Positive | 1 |
| UKET, Baseline, Negative | 5 |
| UKET, Baseline, Positive | 1 |
| UKET, Post-Treatment, Negative | 2 |
| UKET, Post-Treatment, Positive | 1 |
| UP, Baseline, Negative | 6 |
| UP, Baseline, Positive | 0 |
| UP, Post-Treatment, Negative | 2 |
| UP, Post-Treatment, Positive | 1 |
| UUBIL, Baseline, Negative | 0 |
| UUBIL, Baseline, Positive | 6 |
| UUBIL, Post-Treatment, Negative | 0 |
| UUBIL, Post-Treatment, Positive | 3 |
The ECOG pef status 5-point scale is used to assess how a participant's disease is progressing, to assess how the disease affects the daily living abilities of the par. and to determine appropriate treatment and prognosis: G0, fully active, able to carry on all pre-disease pef without restriction. G1, restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, example, light house work, office work. G2, ambulatory and capable of all selfcare, but unable to carry out any work activities; up and about \>50% of waking hrs. G3, capable of only limited selfcare; confined to bed or chair \>50% of waking hrs. G4, completely disabled; cannot carry on any selfcare; totally confined to bed or chair. G5, dead. The worst-case during the on-therapy period was determined taking into account both scheduled and unscheduled assessments. Number of par. who improved, had no change, or deteriorated in pef status from BL is summarized.
| Participants | Phase II: GSK2118436 150 mg + GSK1120212 2 mg |
|---|---|
| Improved | 0 |
| No change | 4 |
| Deteriorated | 2 |
SBP and DBP values were graded using (NCI CTCAE version 4.0). SBP was categorized as: G1 (Increase to \>=120 to 140 mmHg), G2 (Increase to \>=140 to \<160 mmHg), and G3 (Increase to \>=160 mmHg). DBP was categorized as: G1 (Increase to \>=80 to \<90 mmHg), G2 (Increase to \>=90 to \<100 mmHg), and G3 (Increase to \>=100 mmHg). The worst-case during the on-therapy period was determined taking into account both scheduled and unscheduled assessments. An increase is defined as an increase in the CTCAE grade relative to the Baseline grade. Participants with missing Baseline values were assumed to have a Baseline value of G0.
| Participants | Phase II: GSK2118436 150 mg + GSK1120212 2 mg |
|---|---|
| SBP, Increase to Grade 2 | 3 |
| SBP, Increase to Grade 3 | 0 |
| DBP, Increase to Grade 2 | 5 |
| DBP, Increase to Grade 3 | 0 |
Change from Baseline in heart rate is categorized as decrease to \<60 bpm, change to normal or no change, and increase to \>100 bpm relative to the Baseline value. Participants with a missing Baseline value are assumed to have a normal Baseline value. Participants were counted twice if the participant's heart rate value decreased to \<60 bpm and increased to \>100 bpm post-Baseline. The worst-case during the on-therapy period was determined taking into account both scheduled and unscheduled assessments.
| Participants | Phase II: GSK2118436 150 mg + GSK1120212 2 mg |
|---|---|
| Decrease to <60 bpm | 1 |
| Change to normal or no change | 4 |
| Increase to >100 bpm | 1 |
Change from Baseline in temperature is categorized as a decrease to \<=35 degrees C, change to normal or no change as 35-38 degrees C, and increase to \>=38 degrees C relative to the Baseline value. Participants with a missing Baseline value are assumed to have a normal Baseline value. Participants were counted twice if the participant temperature value decreased to \<=35 degrees C and increased to \>=38 degrees C post-Baseline. The worst-case during the on-therapy period was determined taking into account both scheduled and unscheduled assessments.
| Participants | Phase II: GSK2118436 150 mg + GSK1120212 2 mg |
|---|---|
| Decrease to <=35 degrees C | 2 |
| Change to normal or no change | 4 |
| Increase to >=38 degrees C | 0 |
Oxygen saturation measures the capacity of blood to transport oxygen to other parts of the body. Oxygen binds to hemoglobin in red blood cells when moving through the lungs. A pulse oximeter uses two frequencies of light (red and infrared) to determine the percentage of hemoglobin in the blood that is saturated with oxygen, that is called as blood oxygen saturation, or SpO2. Change from Baseline was calculated as the individual post-Baseline value (Days 8 and 15; Weeks 3 to 132 and post-treatment Visit) minus the Baseline value. The Baseline value is defined as the last pre-treatment value observed.
| Percentage of oxygen in blood | Phase II: GSK2118436 150 mg + GSK1120212 2 mg |
|---|---|
| Day 8, n=6 | -0.2 ± 0.98 |
| Day 15, n=6 | 0.3 ± 1.51 |
| Week 3, n=6 | 0.5 ± 0.84 |
| Week 8, n=6 | 0.5 ± 1.05 |
| Week 12, n=6 | -0.2 ± 0.98 |
| Week 16, n=6 | 0.3 ± 1.51 |
| Week 20, n=5 | -1.0 ± 1.58 |
| Week 24, n=5 | 0.2 ± 1.64 |
| Week 28, n=5 | -0.2 ± 0.84 |
| Week 32, n=5 | -0.6 ± 1.14 |
| Week 36, n=5 | -0.4 ± 1.34 |
| Week 40, n=5 | 0.0 ± 1.58 |
| Week 44, n=4 | -1.3 ± 2.22 |
| Week 48, n=4 | 1.0 ± 1.41 |
| Week 52, n=3 | 1.0 ± 1.73 |
| Week 56, n=3 | -0.7 ± 0.58 |
| Week 60, n=3 | -0.3 ± 1.15 |
| Week 64, n=3 | -0.3 ± 0.58 |
| Week 68, n=3 | 0.0 ± 1.00 |
| Week 72, n=3 | -0.7 ± 1.53 |
| Week 76, n=3 | -1.0 ± 0.00 |
| Week 80, n=3 | 0.0 ± 1.00 |
| Week 84, n=3 | -0.3 ± 1.53 |
| Week 88, n=3 | -0.3 ± 1.53 |
| Week 92, n=3 | 0.3 ± 0.58 |
| Week 96, n=3 | -0.3 ± 0.58 |
| Week 100, n=3 | -0.7 ± 1.15 |
| Week 104, n=3 | -0.3 ± 1.53 |
| Week 108, n=3 | 0.0 ± 1.00 |
| Week 112, n=3 | 0.0 ± 1.00 |
| Week 116, n=3 | -0.7 ± 0.58 |
| Week 120, n=2 | -0.5 ± 0.71 |
| Week 124, n=1 | -2.0 ± NA |
| Week 128, n=1 | 1.0 ± NA |
| Week 132, n=1 | -2.0 ± NA |
| Post-Treatment, n=3 | 1.3 ± 0.58 |
Mean change in body weight from baseline was determined. Change from Baseline was calculated as the individual post-Baseline value (Weeks 3 to 132 and post-treatment Visit) minus the Baseline value. The Baseline value is defined as the last pre-treatment value observed.
| Kg | Phase II: GSK2118436 150 mg + GSK1120212 2 mg |
|---|---|
| Week 3, n=6 | -0.68 ± 0.538 |
| Week 8, n=6 | -0.22 ± 0.553 |
| Week 12, n=6 | -0.30 ± 1.273 |
| Week 16, n=6 | 0.05 ± 1.947 |
| Week 20, n=5 | -0.32 ± 2.318 |
| Week 24, n=5 | 0.06 ± 2.243 |
| Week 28, n=5 | 0.18 ± 2.500 |
| Week 32, n=5 | 0.42 ± 2.607 |
| Week 36, n=5 | 0.98 ± 3.016 |
| Week 40, n=5 | 0.62 ± 2.734 |
| Week 44, n=4 | 0.80 ± 3.790 |
| Week 48, n=4 | 0.68 ± 3.527 |
| Week 52, n=3 | 1.27 ± 3.993 |
| Week 56, n=3 | 2.23 ± 3.932 |
| Week 60, n=3 | 2.83 ± 3.879 |
| Week 64, n=3 | 2.70 ± 4.246 |
| Week 68, n=3 | 2.87 ± 4.143 |
| Week 72, n=3 | 2.87 ± 4.165 |
| Week 76, n=3 | 3.63 ± 2.793 |
| Week 80, n=3 | 3.43 ± 4.007 |
| Week 84, n=3 | 4.37 ± 4.008 |
| Week 88, n=3 | 3.80 ± 3.905 |
| Week 92, n=3 | 4.13 ± 3.496 |
| Week 96, n=3 | 4.13 ± 3.630 |
| Week 100, n=3 | 3.53 ± 3.219 |
| Week 104, n=3 | 4.00 ± 4.557 |
| Week 108, n=3 | 3.93 ± 4.800 |
| Week 112, n=3 | 3.60 ± 4.649 |
| Week 116, n=3 | 4.20 ± 4.859 |
| Week 120, n=2 | 5.95 ± 2.192 |
| Week 124, n=1 | 7.50 ± NA |
| Week 128, n=1 | 5.80 ± NA |
| Week 132, n=1 | 5.30 ± NA |
| Post-Treatment, n=3 | 0.13 ± 2.155 |
Single 12-lead ECGs were performed at Baseline, Weeks 3 to 132 and post-treatment Visit. ECG findings were categorized as: normal, abnormal - CS, or abnormal - NCS, as determined by the investigator.
| Participants | Phase II: GSK2118436 150 mg + GSK1120212 2 mg |
|---|---|
| Baseline, Normal, n=6 | 5 |
| Baseline, Abnormal-NCS, n=6 | 1 |
| Baseline, Abnormal-CS, n=6 | 0 |
| Week 3, Normal, n=6 | 4 |
| Week 3, Abnormal-NCS, n=6 | 2 |
| Week 3, Abnormal-CS, n=6 | 0 |
| Week 12, Normal, n=6 | 4 |
| Week 12, Abnormal-NCS, n=6 | 2 |
| Week 12, Abnormal-CS, n=6 | 0 |
| Week 24, Normal, n=5 | 3 |
| Week 24, Abnormal-NCS, n=5 | 2 |
| Week 24, Abnormal-CS, n=5 | 0 |
| Week 36, Normal, n=5 | 2 |
| Week 36, Abnormal-NCS, n=5 | 3 |
| Week 36, Abnormal-CS, n=5 | 0 |
| Week 48, Normal, n=4 | 3 |
| Week 48, Abnormal-NCS, n=4 | 1 |
| Week 48, Abnormal-CS, n=4 | 0 |
| Week 60, Normal, n=3 | 2 |
| Week 60, Abnormal-NCS, n=3 | 1 |
| Week 60, Abnormal-CS, n=3 | 0 |
| Week 72, Normal, n=3 | 2 |
| Week 72, Abnormal-NCS, n=3 | 1 |
| Week 72, Abnormal-CS, n=3 | 0 |
| Week 84, Normal, n=3 | 1 |
| Week 84, Abnormal-NCS, n=3 | 2 |
| Week 84, Abnormal-CS, n=3 | 0 |
| Week 96, Normal, n=3 | 1 |
| Week 96, Abnormal-NCS, n=3 | 2 |
| Week 96, Abnormal-CS, n=3 | 0 |
| Week 108, Normal, n=3 | 1 |
| Week 108, Abnormal-NCS, n=3 | 2 |
| Week 108, Abnormal-CS, n=3 | 0 |
| Week 120, Normal, n=2 | 1 |
| Week 120, Abnormal-NCS, n=2 | 1 |
| Week 120, Abnormal-CS, n=2 | 0 |
| Week 132, Normal, n=1 | 0 |
| Week 132, Abnormal-NCS, n=1 | 1 |
| Week 132, Abnormal-CS, n=1 | 0 |
| Post-Treatment, Normal, n=3 | 3 |
| Post-Treatment, Abnormal-NCS, n=3 | 0 |
| Post-Treatment, Abnormal-CS, n=3 | 0 |
Absolute change from Baseline in LVEF were summarized at each scheduled assessment time and in the worst-case post Baseline. Only the post Baseline assessments that used the same method (ECHO or MUGA) as the Baseline assessments were used to derive the change from Baseline. The change from Baseline was categorized as: any increase; no change; 0-\<10 Decrease, 10-19 Decrease, \>=20 Decrease, \>=10 Decrease and \>= LLN, \>=10 Decrease and below LLN, \>=20 Decrease and \>=LLN and \>=20 Decrease and below LLN. The worst-case during the on-therapy period was determined taking into account both scheduled and unscheduled assessments.
| Participants | Phase II: GSK2118436 150 mg + GSK1120212 2 mg |
|---|---|
| Any Increase | 1 |
| No change | 0 |
| 0-<10 Decrease | 3 |
| 10-19 Decrease | 2 |
| >=20 Decrease | 0 |
| >=10 Decrease and >=LLN | 2 |
| >=10 Decrease and below LLN | 0 |
| >=20 Decrease and >=LLN | 0 |
| >=20 Decrease and below LLN | 0 |
Collected over On treatment serious adverse events (SAEs) and non-serious adverse events (AEs) were collected from the start of investigational product (IP) until 30 days after the last dose of IP (average of 1.38 years).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase I: GSK2118436 150 mg + GSK1120212 2 mg | — | 1/6 (16.7%) | 6/6 (100%) |
| Phase II: GSK2118436 150 mg + GSK1120212 2 mg | — | 0/6 (0%) | 6/6 (100%) |
| Event | Phase I: GSK2118436 150 mg + GSK1120212 2 mg | Phase II: GSK2118436 150 mg + GSK1120212 2 mg |
|---|---|---|
| PneumonitisRespiratory, thoracic and mediastinal disorders | 1/6 | 0/6 |
| Event | Phase I: GSK2118436 150 mg + GSK1120212 2 mg | Phase II: GSK2118436 150 mg + GSK1120212 2 mg |
|---|---|---|
| PyrexiaGeneral disorders | 5/6 | 4/6 |
| Oedema peripheralGeneral disorders | 2/6 | 4/6 |
| Aspartate aminotransferase increasedInvestigations | 4/6 | 4/6 |
| ErythemaSkin and subcutaneous tissue disorders | 4/6 | 1/6 |
| Rash maculo-papularSkin and subcutaneous tissue disorders | 4/6 | 0/6 |
| NasopharyngitisInfections and infestations | 4/6 | 2/6 |
| Blood alkaline phosphatase increasedInvestigations | 3/6 | 2/6 |
| StomatitisGastrointestinal disorders | 2/6 | 3/6 |
| Dermatitis acneiformSkin and subcutaneous tissue disorders | 3/6 | 1/6 |
| AlopeciaSkin and subcutaneous tissue disorders | 3/6 | 0/6 |
| Age, Continuous(Years) | Phase I: GSK2118436 150 mg + GSK1120212 2 mg | Phase II: GSK2118436 150 mg + GSK1120212 2 mg | Total |
|---|---|---|---|
| Mean | 52.2 ± 19.83 | 59.0 ± 10.99 | 55.6 ± 15.70 |
| Sex: Female, Male(Participants) | Phase I: GSK2118436 150 mg + GSK1120212 2 mg | Phase II: GSK2118436 150 mg + GSK1120212 2 mg | Total |
|---|---|---|---|
| Female | 5 | 2 | 7 |
| Male | 1 | 4 | 5 |
| Race/Ethnicity, Customized(Participants) | Phase I: GSK2118436 150 mg + GSK1120212 2 mg | Phase II: GSK2118436 150 mg + GSK1120212 2 mg | Total |
|---|---|---|---|
| Asian - Japanese Heritage | 6 | 6 | 12 |
This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
GlaxoSmithKline